DRI searches Cipla’s Mumbai office and Bhiwandi depot over imported drug classification

The Directorate of Revenue Intelligence conducted searches at Cipla's Mumbai office and Bhiwandi depot regarding the classification of an imported pharmaceutical product. Cipla stated the proceedings will not have a material impact on its operations and is cooperating with authorities.
Why it matters
Regulatory scrutiny of pharmaceutical import classifications can impact supply chains and compliance costs for major drug manufacturers.
New Delhi The Directorate of Revenue Intelligence (DRI), Mumbai zonal unit, has conducted searches at pharmaceutical company Cipla’s office in Vikhroli and its depot in Bhiwandi, Thane, over the classification or exemption of an imported finished pharmaceutical product. The searches were conducted on Monday under Section 105 of the Customs Act, 1962. Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar The partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports its strategy to build a strong oncology-focused portfolio.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in